4 completed, 3 active not recruiting, 2 withdrawn, 1 terminated. 8 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 4, Withdrawn 2, Active not recruiting 1, Terminated 1 |
| Phase 3 | 3 | Active not recruiting 3 |
Follow setrusumab: new trials by email Literature Review of setrusumab trials Research Report on setrusumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta setrusumab - Osteogenesis Imperfecta | Phase 3 | Active not recruiting | Ultragenyx Pharmaceutical Inc | 6 | 2024-10-25 | 2026-09-28 |
| Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta Bisphosphonate, Setrusumab - Osteogenesis Imperfecta | Phase 3 | Active not recruiting | Ultragenyx Pharmaceutical Inc | 69 | 2023-06-14 | 2026-10-20 |
| Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta Setrusumab - Osteogenesis Imperfecta | Phase 2 | Terminated | Ultragenyx Pharmaceutical Inc | 2 | 2022-04-28 | 2025-07-23 |
| Setrusumab vs Placebo for Osteogenesis Imperfecta Setrusumab, Placebo - Osteogenesis Imperfecta | Phase 2 / Phase 3 | Active not recruiting | Ultragenyx Pharmaceutical Inc | 183 | 2022-02-21 | 2026-10-20 |
| An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta BPS804 - Osteogenesis Imperfecta | Phase 2 | Withdrawn | Ultragenyx Pharmaceutical Inc | 2017-10-31 | 2023-07-03 | |
| A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804 setrusumab, Calcium, Vitamin D - Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type III | Phase 2 | Completed | Ultragenyx Pharmaceutical Inc | 112 | 2017-09-11 | 2023-07-05 |
| Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney Disease BPS804, Placebo - Chronic-kidney Disease Stage 5D on Stable Hemodialysis | Phase 2 | Withdrawn | Ultragenyx Pharmaceutical Inc | 2013-08-01 | 2022-09-14 | |
| Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP) BPS804 - Hypophosphatasia | Phase 2 | Completed | Ultragenyx Pharmaceutical Inc | 8 | 2011-07-01 | 2022-09-16 |
| Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density BPS804 20mg/Kg, Placebo to 20mg/Kg BPS804 - Osteopenia, Osteoporosis | Phase 2 | Completed | Ultragenyx Pharmaceutical Inc | 44 | 2011-07-01 | 2022-09-15 |
| Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta BPS804 - Osteogenesis Imperfecta | Phase 2 | Completed | Ultragenyx Pharmaceutical Inc | 10 | 2011-06-01 | 2021-05-11 |
Osteogenesis Imperfecta (7) · Bone Diseases, Metabolic (1) · Connective Tissue Diseases (1) · Fractures, Bone (1) · Hypophosphatasia (1) · Osteogenesis imperfecta, type 3 (1) · Osteoporosis (1)
Ultragenyx Pharmaceutical Inc (10)
United States (7) · Canada (4) · France (3) · Germany (3) · Italy (2) · Netherlands (2) · Poland (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Brazil (1) · Denmark (1) · Japan (1) · Portugal (1) · Turkey (Türkiye) (1)
PMID 42470570, PMID 28436937, PMID 39012717
2016 (1), 2023 (1)